

Contents

	Page
CHAPTER 1 General introduction	9
 Part-1: Characterization of MUTZ-3 as a human IDC/LC cell line model	
CHAPTER 2 Transcriptional profiling of human skin-resident dermal dendritic cells and Langerhans cells: differential activation states suggest distinct functions <i>Submitted for publication.</i>	37
CHAPTER 3 A CD34+ human cell line model of myeloid dendritic cell differentiation: evidence for a CD14+CD11b+ Langerhans cell precursor <i>Journal of Leukocyte Biology, 2006, 80(6):1337-44</i>	53
CHAPTER 4 Transcriptional profiling of MUTZ-3-derived Interstitial dendritic cells and Langerhans cells <i>To be submitted.</i>	63
 Part-2: Development of MUTZ-3-derived IDC/LC for tumor immunotherapy	
CHAPTER 5a In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line <i>Cancer Immunology Immunotherapy 2006, 55 (12): 1480-90</i>	75
CHAPTER 5b Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapy <i>The Journal of Immunology 2007, 179 (3): 2005–2012.</i>	89
CHAPTER 6 The novel bispecific diabody α CD40/ α CD28 strengthens leukemic dendritic cell induced T cell reactivity <i>British Journal of Haematology 2008; in press</i>	99
CHAPTER 7 Inducing anti-tumor T cell immunity: comparative functional analysis of Interstitial versus Langerhans dendritic cells in a human cell line model <i>Submitted for publication.</i>	117

CHAPTER 8	Discussion: Human dendritic cell line models for DC differentiation and clinical DC vaccination studies <i>Submitted for publication.</i>	139
CHAPTER 9	Summary	159
CHAPTER 10	Nederlandse samenvatting	165
Curriculum vitae and publication list		173
Dankwoord		177